Rezolute reported topline data from its Phase 3 sunRIZE study in congenital hyperinsulinism showing that ersodetug did not meet the primary endpoint of reducing average weekly hypoglycemia events versus placebo, nor the key secondary endpoint of reducing time in hypoglycemia by continuous glucose monitoring. At the 10 mg/kg dose, patients saw an approximate 45% reduction in weekly events by self-monitored blood glucose versus a 40% improvement in the placebo arm, and a roughly 25% reduction in time in hypoglycemia on CGM versus a 5% increase on placebo; neither comparison reached statistical significance. Target exposures were achieved across ages, safety was generally manageable, and most participants rolled into open-label extension, with hypersensitivity reactions infrequent and hypertrichosis the most common adverse event.
The immediate strategic question is whether these trends, despite missing significance, indicate a pharmacologic signal obscured by trial design and small sample size, or whether the mechanism will struggle to deliver clinically reliable benefit across a heterogeneous congenital population. For a program positioned as a universal, downstream approach to hyperinsulinism, the study’s high placebo response and variability complicate the regulatory and commercial path that many in the field viewed as within reach under Breakthrough Therapy Designation.
This matters now because congenital hyperinsulinism remains a high-burden, high-cost pediatric condition where standard options—diazoxide, somatostatin analogs, off-label immunosuppressants, and partial pancreatectomy—carry material trade-offs. Families, pediatric endocrinologists, and specialized centers were primed for a treatment that could reduce episodes, hospitalizations, and the need for surgery. Payers, in turn, will expect unequivocal reductions in severe hypoglycemia, utilization, and caregiver burden to justify premium orphan pricing. A non-significant Phase 3 readout means any case for approval will likely rest on subgroup analyses, refined endpoints, or an additional study, raising timelines and evidence thresholds for market access teams. Competitors targeting the insulin receptor axis or alternative pathways may see an opening, but they also inherit the challenge of defining endpoints that resonate with regulators and payers and hold up against optimized standard of care and trial effects that inflate placebo performance.
For Medical Affairs, the next moves are pivotal. Clarifying endpoint construction, sensor calibration and adherence, age and genotype stratification, baseline severity, and the role of site-level standardization will determine whether a targeted path is feasible. The discordance between event counts by self-monitoring and directionally favorable CGM time-in-hypoglycemia suggests measurement sensitivity and behavioral influences that can be addressed through protocol refinements, centralized analytics, and education. Real-world data from the open-label extension could inform payer-relevant outcomes such as emergency visits, admissions, glucose infusion requirements, and surgical avoidance, but will need careful methodology to overcome selection bias.
The broader backdrop is unforgiving. Late-stage rare endocrine programs are colliding with tighter evidentiary standards, greater reliance on digital endpoints, and investor scrutiny that favors assets with crisp, utilization-based outcomes. Small, heterogeneous trials amplify variance; enrichment designs, adaptive frameworks, and hierarchy-aware statistical plans are becoming table stakes. Rezolute’s ongoing Phase 3 upLIFT trial in tumor-induced hyperinsulinism, with topline results expected in the second half of 2026, may provide a cleaner test of the mechanism where IGF-2 and receptor hyperactivation are prominent, but today’s readout lowers the margin for error.
The question ahead is whether Rezolute can rapidly converge on a narrower, signal-rich population or refined endpoint strategy that converts directional effects into regulatory-grade evidence—and, if not, whether the tumor-HI program becomes the value anchor that keeps the franchise investable.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
